OrphanReach

OrphanReach is a global contract research organization (CRO) exclusively dedicated to the development of orphan drugs and treatments for rare diseases. Founded in 2002, the company provides a full suite of clinical trial management services, including regulatory support, patient recruitment, and clinical monitoring, tailored to the unique challenges of small patient populations. In 2021, OrphanReach was acquired by Clinigen, integrating its specialized rare disease expertise into Clinigen's broader lifecycle management and patient access services. The company operates through a decentralized model, leveraging a global network of experts to support clinical programs across multiple therapeutic areas.